Lupin‘s Board of Directors has approved to increase the limit of investments by Foreign Institutional Investors (FIIs) in the equity share capital of the Company from 33% to 49%, subject to approval of the Members. Reserve Bank of India and any other approvals as may be required.
Approval of the Members shall be obtained at the forthcoming Annual General Meeting
The company’s net profit grew by 56.70% at Rs 1260.43 crore for the year ended March 31, 2013 as compared to Rs 804.37 crore for the year ended March 31, 2012. Its total income has increased by 32.61% to Rs 7145.82 crore for the year from Rs 5388.32 crore for the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.15 |
| Dr. Reddys Labs. | 1350.00 |
| Cipla | 1440.30 |
| Zydus Lifesciences | 1101.50 |
| Lupin | 2342.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: